Business Continuity in Drug Development Due to the COVID-19 Pandemic

Life Sciences, Clinical Trials, Drug Discovery & Development,
  • Wednesday, May 13, 2020

From patient participation alternatives and accelerated vaccine research to operational and data management challenges, COVID-19 has undeniably been a disruptive force on clinical trials, forcing the industry to scramble to keep up – and to stay ahead.

While there are no guarantees about the future, there are known steps that can be taken now to best position yourself to not only keep your trials on track, but adapt and prepare for the inevitable changes of the future. It’s not about just taking short-term actions to navigate immediate concerns. Thinking ahead for business continuity must be more than “taking it one step at a time;” long-term success hinges on long-term thinking and proactive planning.

Join Mary Mattes, Senior Vice President of Global Operations at Synteract, along with Christina Hughes, Chief Operating Officer at Medrio, for a webinar on Business Continuity for Drug Developers Due to the COVID-19 Pandemic on May 13, 2020, to evaluate possible scenarios for the industry as the pandemic’s impacts continue to unfold. Find out how you can best prepare for communication concerns, trial participation, risk management, increasing technology needs and more.

Regardless of the ultimate duration, this pandemic has indelibly changed the business of clinical trials forever. Whether your organization simply “rides this out” or proactively changes for the future, responding – or even innovating – now and securing your position ahead of the curve, depends on understanding today’s rapidly evolving landscape.

Speakers

http://Mary%20Mattes,%20Synteract

Mary Mattes, Senior Vice President, Global Operations, Synteract

Mary Mattes is focused on the quality delivery of project management, clinical operations, data management, biostatistics, regulatory affairs, safety and medical writing services globally. With broad experience in clinical trial execution, Mattes defines and develops her teams to meet the demands of today’s clinical research environment.  Applying 20+ years of experience in technology and regulatory requirements for Phase I-IV trials, Mattes also partners with the Synteract leadership team to select and implement technology to bring clinical trials to life.

Message Presenter
http://Christina%20N.%20Hughes,%20Medrio

Christina N. Hughes, Chief Operating Officer, Medrio

Christina Hughes is the Chief Operating Officer of Medrio responsible for managing global operations to deliver Medrio’s eSuite of clinical trial solutions to pharmaceutical, medical device and biotech clients.

Hughes has over 20 years of experience in the clinical trials industry focused on delivering high quality solutions through the innovative use of technology. Prior to joining Medrio, Hughes held executive positions at Bracket (now Signant Health), AiCure and ERT.

Hughes holds a BS from Yale University and an MBA from University of Pennsylvania’s The Wharton School.

 

Message Presenter

Who Should Attend?

The webinar will appeal to all drug developers operating within the time of the COVID-19 pandemic in the areas of:

  • Clinical Affairs
  • Clinical R&D
  • Clinical Research
  • Clinical Pharmacology
  • Clinical Operations
  • Project Management
  • Regulatory Affairs
  • Medical Affairs

What You Will Learn

In this webinar, attendees will learn how to:

  • Maintain communication pathways as the situation continues to change
  • Customize remote monitoring plans to stay nimble
  • Adapt to the evolution of data collection – (EDC, DDC, ePRO, eConsent)
  • What to anticipate for the future when COVID-19’s impact recedes 

 

Xtalks Partner

Synteract

With employees across 21 countries, Synteract is an innovative, full-service CRO supporting biopharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and 750,000 patients. Greater than 245 of its 4,000 studies have been in pediatric populations. In addition to pediatrics clinical trials, Synteract offers a notable depth of therapeutic expertise in dermatology, neurodegenerative, oncology and immunotherapy and rare/orphan disease studies.

Media Partner

The original site for employees in the pharma, medical, diagnostic and related industries.  Our hand-curated daily news feed and active message forums will keep you informed.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account